Alnylam Pharmaceuticals ALNY Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.66B+71.2% | $968.65M+18.9% | $814.88M-6.2% | $868.56M+5.6% | ||
| $1.25B-27.3% | $1.72B+6.5% | $1.62B+24.5% | $1.3B-16.2% | ||
| $777.57M+91.8% | $405.31M+23.6% | $327.79M+37.7% | $237.96M+19.8% | ||
| $82.72M+5.4% | $78.51M-11.9% | $89.15M-30.9% | $128.96M+49.3% | ||
| $4.05B+22.9% | $3.3B+10.5% | $2.98B+10.8% | $2.69B-4.1% | ||
| $513.15M+2.1% | $502.78M-4.4% | $526.06M+0.5% | $523.49M+4.3% | ||
| $4.97B+17.1% | $4.24B+10.7% | $3.83B+8.0% | $3.55B-2.7% | ||
| $4.85M-91.3% | $55.48M-46.0% | $102.75M+144% | $42.11M-71.8% | ||
| $1.47B+23.6% | $1.19B+22.6% | $967.79M+26.0% | $767.92M+10.4% | ||
| $4.18B+0.1% | $4.17B+3.0% | $4.05B+9.3% | $3.7B+21.3% | ||
| 250M+19,235% | 1.3M+2.7% | 1.3M+1.5% | 1.2M+3.2% | ||
| -$6.7B+8.0% | -$7.29B-4.0% | -$7.01B-6.7% | -$6.57B-20.8% | ||
| $789.18M+1,076% | $67.09M+130% | -$220.64M-39.5% | -$158.22M-127% | ||
| $4.97B+17.1% | $4.24B+10.7% | $3.83B+8.0% | $3.55B-2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alnylam Pharmaceuticals's total assets?
- Alnylam Pharmaceuticals (ALNY) holds $5.1B in total assets, up 21.7% year over year.
- How much debt does Alnylam Pharmaceuticals have?
- Alnylam Pharmaceuticals carries $263.7M in total debt against $1.1B of shareholders' equity, a debt-to-equity ratio of 0.25.
- How much cash does Alnylam Pharmaceuticals have?
- Alnylam Pharmaceuticals holds $1.7B in cash and equivalents.
- Can Alnylam Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.13 — current assets exceed current liabilities.
- Where does Alnylam Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
